aldeyra therapeutics shares were up 11 to 1161 after the company said it saw positive topline results from its phase 3 clinical trial of 025 reproxalap ophthalmic solution an investigational new drug in patients with allergic conjunctivitis the stock hit its 52week high of 1197 earlier in the session and is up 242 in the past 12 months the biotechnology company said the clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints the primary efficacy endpoint was change from baseline in patientreported ocular itching score on a 0 to 4 point scale over a majority of 11 time points from 110 to 210 minutes after allergen chamber entry the key secondary endpoint was change from baseline in ocular redness on a 0 to 4 point scale over the duration of the allergen chamber about 312 hours relative to patients treated with vehicle patients treated with reproxalap reported statistically significant ocular itching score reduction across all 11 prespecified primary endpoint comparisons from 110 to 210 minutes in the allergen chamber the reproxalaptreated patients demonstrated statistically significant reduction from baseline compared to vehicle for the key secondary endpoint of investigatorassessed ocular redness over the duration of the allergen chamber there were no observed safety or tolerability concerns in the trial the most common adverse event was mild and transient instillation site irritation no patients discontinued due to adverse events and 130 of 131 randomized patients completed the clinical trial a new drug application of reproxalap for the treatment of dry eye disease is under review at the us food and drug administration